Search results
FDA OKs Iqirvo, First-in-Class PPAR Treatment for PBC
Medscape· 4 days agoIqirvo (elafibranor) is indicated for adults with primary biliary cholangitis who do not respond to or cannot tolerate ursodeoxycholic acid.
Coping With Graft-Versus-Host-Disease
Verywell Health via Yahoo News· 3 days agoLearn how to cope with your graft-versus-host-disease day-to-day, including how to eat to reduce symptoms, exercise, manage finances, and find support.
The Unknowns Challenge Prostate Cancer Patient Partners
WebMD· 5 days agoTreatment of lower-risk prostate cancer with surgery or radiation can take its toll on men not just because it brings the risk of death, but because it carries side
Opinion | Was the FDA Panel Right to Recommend Against MDMA Approval?
MedPage Today· 4 days agoUntreated mental health concerns remain devastating for our nation, and there is an ongoing need for...
Debulking Does Not Improve Survival in Multiorgan Mets CRC
Medscape· 4 days agoInvestigators found that tumor debulking in multiorgan metastatic colorectal cancer will not extend...
5 Symptoms of Hemorrhoids Everyone With a Butt Should Know
Self via Yahoo News· 5 days agoOthers are more serious than hemorrhoids but treatable, like an ulcer, an anal fissure, a polyp, or...
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients...
The Pilot News· 7 days agoEli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide ...
The 'Useless' Appendix Is More Fascinating Than We Thought
Medscape· 5 days agoWhen doctors and patients consider the appendix, it's often with urgency. Thus, despite recent...
Tribeca Film ‘Group Therapy’ Explores Comedians And Mental Health
Forbes· 2 days agoDirected by Neil Berkeley and produced by Hartbeat, Kevin Hart’s multi-platform entertainment...
Components of Self-Management for People With Schizophrenia
Medscape· 2 days agoFor this Care Cues conversation today, I'm joined by my colleague, Dr Corinne Cather. Freudenreich:...